Literature DB >> 17229843

Beta cells cannot directly prime diabetogenic CD8 T cells in nonobese diabetic mice.

James de Jersey1, Sarah L Snelgrove, Stephanie E Palmer, Simon A Teteris, Arno Mullbacher, Jacques F A P Miller, Robyn M Slattery.   

Abstract

Type 1 diabetes (T1D) is caused by the destruction of insulin-producing islet beta cells. CD8 T cells are prevalent in the islets of T1D patients and are the major effectors of beta cell destruction in nonobese diabetic (NOD) mice. In addition to their critical involvement in the late stages of diabetes, CD8 T cells are implicated in the initiation of disease. NOD mice, in which the beta2-microglobulin gene has been inactivated by gene targeting (NOD.beta2M-/-), have a deficiency in CD8 T cells and do not develop insulitis, which suggests that CD8 T cells are required for the initiation of T1D. However, neither in humans nor in NOD mice have the immunological requirements for diabetogenic CD8 T cells been precisely defined. In particular, it is not known in which cell type MHC class I expression is required for recruitment and activation of CD8 T cells. Here we have generated transgenic NOD mice, which lack MHC class I on mature professional antigen-presenting cells (pAPCs). These "class I APC-bald" mice developed periislet insulitis but not invasive intraislet insulitis, and they never became diabetic. Recruitment to the islet milieu does not therefore require cognate interaction between CD8 T cells and MHC class I on mature pAPCs. Conversely, such an interaction is critically essential to allow the crucial shift from periislet insulitis to invasive insulitis. Importantly, our findings demonstrate unequivocally that CD8 T cells cannot be primed to become diabetogenic by islet beta cells alone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17229843      PMCID: PMC1773057          DOI: 10.1073/pnas.0610057104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens.

Authors:  Steffen Jung; Derya Unutmaz; Phillip Wong; Gen-Ichiro Sano; Kenia De los Santos; Tim Sparwasser; Shengji Wu; Sri Vuthoori; Kyung Ko; Fidel Zavala; Eric G Pamer; Dan R Littman; Richard A Lang
Journal:  Immunity       Date:  2002-08       Impact factor: 31.745

Review 2.  Parallels and distinctions between T and NKT cell development in the thymus.

Authors:  Stuart P Berzins; Adam P Uldrich; Daniel G Pellicci; Finlay McNab; Yoshihiro Hayakawa; Mark J Smyth; Dale I Godfrey
Journal:  Immunol Cell Biol       Date:  2004-06       Impact factor: 5.126

3.  Dendritic cells are sufficient to cross-present self-antigens to CD8 T cells in vivo.

Authors:  C Kurts; M Cannarile; I Klebba; T Brocker
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

4.  Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting.

Authors:  H Gu; Y R Zou; K Rajewsky
Journal:  Cell       Date:  1993-06-18       Impact factor: 41.582

5.  The murine E alpha immune response gene.

Authors:  D J Mathis; C O Benoist; V E Williams; M R Kanter; H O McDevitt
Journal:  Cell       Date:  1983-03       Impact factor: 41.582

6.  Cross-priming of diabetogenic T cells dissociated from CTL-induced shedding of beta cell autoantigens.

Authors:  Jun Yamanouchi; Joan Verdaguer; Bingye Han; Abdelaziz Amrani; Pau Serra; Pere Santamaria
Journal:  J Immunol       Date:  2003-12-15       Impact factor: 5.422

7.  Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors.

Authors:  S W Christianson; L D Shultz; E H Leiter
Journal:  Diabetes       Date:  1993-01       Impact factor: 9.461

8.  HLA-A*0201-restricted T cells from humanized NOD mice recognize autoantigens of potential clinical relevance to type 1 diabetes.

Authors:  Toshiyuki Takaki; Michele P Marron; Clayton E Mathews; Stephen T Guttmann; Rita Bottino; Massimo Trucco; Teresa P DiLorenzo; David V Serreze
Journal:  J Immunol       Date:  2006-03-01       Impact factor: 5.422

9.  Beta cell MHC class I is a late requirement for diabetes.

Authors:  Emma E Hamilton-Williams; Stephanie E Palmer; Brett Charlton; Robyn M Slattery
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-15       Impact factor: 11.205

10.  Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model.

Authors:  Shannon Turley; Laurent Poirot; Masakazu Hattori; Christophe Benoist; Diane Mathis
Journal:  J Exp Med       Date:  2003-11-17       Impact factor: 14.307

View more
  14 in total

1.  A minor subset of Batf3-dependent antigen-presenting cells in islets of Langerhans is essential for the development of autoimmune diabetes.

Authors:  Stephen T Ferris; Javier A Carrero; James F Mohan; Boris Calderon; Kenneth M Murphy; Emil R Unanue
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

Review 2.  Cross-priming in health and disease.

Authors:  Christian Kurts; Bruce W S Robinson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106

Review 3.  Use of nonobese diabetic mice to understand human type 1 diabetes.

Authors:  Terri C Thayer; S Brian Wilson; Clayton E Mathews
Journal:  Endocrinol Metab Clin North Am       Date:  2010-07-08       Impact factor: 4.741

Review 4.  The role of dendritic cells in autoimmunity.

Authors:  Dipyaman Ganguly; Stefan Haak; Vanja Sisirak; Boris Reizis
Journal:  Nat Rev Immunol       Date:  2013-07-05       Impact factor: 53.106

Review 5.  The Biology and Underlying Mechanisms of Cross-Presentation of Exogenous Antigens on MHC-I Molecules.

Authors:  Freidrich M Cruz; Jeff D Colbert; Elena Merino; Barry A Kriegsman; Kenneth L Rock
Journal:  Annu Rev Immunol       Date:  2017-01-11       Impact factor: 28.527

Review 6.  Antigen presentation events in autoimmune diabetes.

Authors:  Boris Calderon; Emil R Unanue
Journal:  Curr Opin Immunol       Date:  2011-12-15       Impact factor: 7.486

Review 7.  Type 1 diabetes genetic susceptibility and dendritic cell function: potential targets for treatment.

Authors:  Chie Hotta-Iwamura; Kristin V Tarbell
Journal:  J Leukoc Biol       Date:  2016-01-20       Impact factor: 4.962

Review 8.  Autoreactive T cells in type 1 diabetes.

Authors:  Alberto Pugliese
Journal:  J Clin Invest       Date:  2017-08-01       Impact factor: 14.808

9.  Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A.

Authors:  Sergey Nejentsev; Joanna M M Howson; Neil M Walker; Jeffrey Szeszko; Sarah F Field; Helen E Stevens; Pamela Reynolds; Matthew Hardy; Erna King; Jennifer Masters; John Hulme; Lisa M Maier; Deborah Smyth; Rebecca Bailey; Jason D Cooper; Gloria Ribas; R Duncan Campbell; David G Clayton; John A Todd
Journal:  Nature       Date:  2007-11-14       Impact factor: 49.962

10.  Antibody combination therapy targeting CD25, CD70 and CD8 reduces islet inflammation and improves glycaemia in diabetic mice.

Authors:  T Alkhamis; J Barbic; T Crnogorac-Jurcevic; R E Greenlaw; M Peakman; S Jurcevic
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.